Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillinase-susceptible penicillin, and tazobactam, a beta-lactamase inhibitor. It is effective against many Gram-positive, Gram-negative, and anaerobic bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections * Community-acquired pneumonia * Hospital-acquired pneumonia (including ventilator-associated pneumonia) * Febrile neutropenia (empiric treatment) * Bacterial infections involving susceptible strains of *Pseudomonas aeruginosa* ## Adult Dosing The standard adult dose is 3.375 grams every 6 hours or 4.5 grams every 6 or 8 hours, administered intravenously over 30 minutes. The choice between 6-hour and 8-hour intervals and the specific dose depends on the indication and severity of infection. * **Complicated intra-abdominal infections:** 3.375 g every 6 hours or 4.5 g every 8 hours. Duration typically 4-7 days. * **Complicated skin and skin structure infections:** 3.375 g every 6 hours. Duration typically 7-10 days. * **Community-acquired pneumonia:** 3.375 g every 6 hours. Duration typically 5-7 days. * **Hospital-acquired pneumonia:** 4.5 g every 6 or 8 hours. Duration typically 7 days. * **Febrile neutropenia:** 4.5 g every 6 or 8 hours. Duration typically 7 days or until resolution of neutropenia. Dosing may be further guided by pathogen susceptibility and clinical response. Some severe infections may benefit from higher doses or more frequent administration, but the maximum recommended dose is typically 4.5 grams every 6 hours. ## Pediatric Dosing Dosing for pediatric patients depends on age, weight, and indication. * **Patients ≥ 2 months of age:** Dosing is typically based on the piperacillin component. * **Complicated intra-abdominal infections, complicated skin and skin structure infections, hospital-acquired pneumonia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose administered intravenously every 8 hours for patients weighing < 40 kg, and every 6 hours for patients weighing ≥ 40 kg. * **Febrile neutropenia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose administered intravenously every 6 hours for patients weighing < 40 kg, and every 8 hours for patients weighing ≥ 40 kg. * **Maximum dose:** Avoid exceeding the adult maximum daily dose (e.g., 4.5 g every 6 hours). ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No adjustment needed. * CrCl 20-40 mL/min: 2.25 g every 6 hours or 3.375 g every 8 hours. * CrCl < 20 mL/min: 2.25 g every 8 hours or 3.375 g every 12 hours. * For hemodialysis patients, administer the recommended dose at the end of dialysis and repeat every 8 hours. ## Contraindications * Known severe hypersensitivity to piperacillin, tazobactam, other penicillinase-resistant penicillins, or any component of the formulation. * History of immediate or generalized reaction (anaphylaxis) to a beta-lactam antibiotic. ## Adverse Effects Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, fever, and injection site reactions. Serious adverse effects include *Clostridioides difficile*-associated diarrhea, seizures (especially with high doses or renal impairment), hypersensitivity reactions (including anaphylaxis), and hematologic effects (e.g., neutropenia, thrombocytopenia). ## Key Drug Interactions * **Probenecid:** May increase piperacillin/tazobactam serum concentrations. * **Aminoglycosides:** Concurrent use may have synergistic activity but also an increased risk of nephrotoxicity. Monitor renal function closely. * **Vecuronium:** Piperacillin may prolong the neuromuscular blockade of vecuronium. * **Warfarin:** Piperacillin may decrease the efficacy of warfarin; monitor INR closely. * **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels. ## Monitoring * Renal function (especially in patients with impaired renal function or receiving nephrotoxic agents). * Liver function tests. * Complete blood count (CBC) with differential and platelet count, particularly with prolonged therapy. * Signs and symptoms of infection for clinical response. * Signs and symptoms of hypersensitivity reactions. * *Clostridioides difficile* testing if diarrhea occurs. ## Clinical Pearls * Piperacillin/tazobactam has a broad spectrum of activity, including *Pseudomonas aeruginosa*. * Reconstituted solutions should be used within 24 hours when refrigerated or within 12 hours at room temperature. * Administration should be over at least 30 minutes to reduce the risk of infusion-related reactions. * Consider de-escalation of therapy once culture and sensitivity results are available. --- ***Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current prescribing information and institutional protocols for complete details regarding dosing, administration, safety, and indications before using any medication.*